SOPH

AI MemoPost-earnings T+3

SOPHiA GENETICS

As of 2026-05-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

July 1 CEO handoff is a real execution checkpoint for a still-unproven scale story • 2026-07-01

Base target: $7 / p=50% prob

Biggest risk

The bear read is that SOPHiA still needs a second-half weighted implementation story to work almost perfectly while remaining loss-making; the market appears to want cleaner proof that signed customers, liquid-biopsy demand, and U.S. health-system wins are becoming durable revenue rather than just backlog [#6K-2026-03-03] [#6K-2026-05-05].

Invalidation

Break below $4 or thesis failure.

What would change my mind?

The post-earnings bull read is that Q1 showed real commercial traction: 22% revenue growth, 117% net dollar retention, record platform usage, 28% U.S. analysis-volume growth, and maintained 20%-22% full-year revenue guidance all support the argument that 2025 signings are starting to convert [#6K-2026-05-05].

Research note

Recommendation

—

Confidence

medium

As of

2026-05-08

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 beat plus reaffirmed 2026 guide now has to convert into back-half revenue ramp
Liquid biopsy, solid tumor, and BioPharma ramps still offer upside if implementations keep converting
The post-earnings bull read is that Q1 showed real commercial traction: 22% revenue growth, 117% net dollar retention, record platform usage, 28% U.S.

BearKey bullets

FX and international operating exposure can pressure reported results even if underlying demand stays healthy, a risk management discussed on the earnings call transcript.
Guidance is still back-half weighted, so any implementation slippage at recently signed customers or large U.S.
systems could disrupt the 2026 ramp [#6K-2026-03-03] [#6K-2026-05-05].

WatchKey bullets

July 1 CEO handoff is a real execution checkpoint for a still-unproven scale story

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $7 (p=50%)

Target spread vs base: +25% / -38%

Scenario probabilities

Bull Target: $9 (p=25%)Base Target: $7 (p=50%)Bear Target: $4 (p=25%)

Commentary

This T+3 follow-up moved the name from unsupported to evidence-backed, but not to high conviction. Primary company materials confirmed a solid Q1 and reiterated outlook, while third-party post-print coverage still framed the reaction as cautious because EPS/loss quality and second-half dependence remain unresolved. We found limited broad analyst-revision evidence beyond a BTIG reiteration, so the clean read is still monitoring-style rather than a strong re-rating call.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 beat plus reaffirmed 2026 guide now has to convert into back-half revenue ramp
Liquid biopsy, solid tumor, and BioPharma ramps still offer upside if implementations keep converting

Scenarios

Bull Target (Scenario probability)

$9 / p=25% prob

Base Target (Scenario probability)

$7 / p=50% prob

Bear Target (Scenario probability)

$4 / p=25% prob

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.18

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-01
July 1 CEO handoff is a real execution checkpoint for a still-unproven scale story
Ross Muken is scheduled to become CEO on July 1, 2026, with founder Jurgi Camblong transitioning to Executive Chairman subject to the June AGM; because SOPHiA is still balancing growth, margin improvement, and commercialization ramp, the leadership handoff could materially affect investor confidence in go-to-market execution and capital discipline [#PR-2026-01-12].
Prob 68.00% • Move 10.00% • Priced-in 58.00%

Short-term Catalysts

Next few weeks

Q1 beat plus reaffirmed 2026 guide now has to convert into back-half revenue ramp
2026-09-30
Q1 revenue rose 22% to $21.7 million, net dollar retention reached 117%, and management reaffirmed 2026 revenue guidance of $92 million-$94 million while saying 18 new core genomic customers signed in Q1 should begin generating revenue over the next twelve months; the near-term test is whether those wins and prior large U.S. health-system signings translate into the expected second-half ramp rather than staying stuck in implementation [#6K-2026-05-05] [#6K-2026-03-03].
Prob 60% • Move 17% • Priced-in 48%

Long-term Catalysts

Months to a year

Liquid biopsy, solid tumor, and BioPharma ramps still offer upside if implementations keep converting
2026-12-31
SOPHiA exited 2025 with over 70 liquid-biopsy customers signed and 21 solid-tumor customers signed, then said in Q1 2026 it had reached 100 customers across 30-plus countries signed to adopt liquid-biopsy or solid-tumor applications while liquid-biopsy analyses grew more than 100% year over year; that creates a credible multi-quarter activation tail, but the value still depends on implementation speed and routine-usage conversion [#6K-2026-03-03] [#6K-2026-05-05].
Prob 46% • Move 23% • Priced-in 36%

Risks

FX and international operating exposure can pressure reported results even if underlying demand stays healthy, a risk management discussed on the earnings call transcript.
Guidance is still back-half weighted, so any implementation slippage at recently signed customers or large U.S. systems could disrupt the 2026 ramp [#6K-2026-03-03] [#6K-2026-05-05].
Recent ATM fundraising and continued focus on cost actions show balance-sheet discipline matters; further dilution risk cannot be ignored if growth-to-profitability timing slips [#6K-2026-03-03] [#6K-2026-05-05].
The July 2026 CEO transition adds governance and execution risk during a period when investors still need commercialization proof [#PR-2026-01-12].
The company remains loss-making, with Q1 IFRS net loss of $19.3 million and adjusted EBITDA loss of $9.2 million, so operating leverage still needs to be proven [#6K-2026-05-05].

Peers

Symbol	Summary
GH	Guardant Health remains the cleanest public overlap for SOPHiA's liquid-biopsy ambitions, but GH is much larger and more scaled, so it works better as a strategic benchmark than a tight valuation comp.
MYGN	Myriad Genetics is an adjacent oncology-diagnostics benchmark with some SOPHiA partnership overlap, but its lab-heavy model makes it an imperfect multiple comp.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-08

Loading AI feed…

Symbol

Summary

Guardant Health remains the cleanest public overlap for SOPHiA's liquid-biopsy ambitions, but GH is much larger and more scaled, so it works better as a strategic benchmark than a tight valuation comp.

MYGN

Myriad Genetics is an adjacent oncology-diagnostics benchmark with some SOPHiA partnership overlap, but its lab-heavy model makes it an imperfect multiple comp.